Avaleht › Väikehemoglobiinhaigus › New York
Väikehemoglobiinhaigus kliinilised uuringud osariigis New York
21 uuringut haiguse Väikehemoglobiinhaigus jaoks otsivad osalejaid osariigis New York.
Linnad osariigis New York
Ametlik uuringutekst (inglise keeles)
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
- Childrens Hospital at Montefiore, The Bronx
VärbamineFaas 3
Vanused 12–100 · Kõik sood · Uuendatud 28. sept 2026 · NCT06439082A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)
- Mount Sinai Hospital, New York
VärbamineFaas 1
Vanused 18 ja vanemad · Kõik sood · Uuendatud 23. sept 2026 · NCT07187973A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
- Columbia University Medical Center_New York_0, New York
- Columbia University Medical Center_New York_0, New York
VärbamineFaas 3
Vanused 2 ja vanemad · Kõik sood · Uuendatud 18. sept 2026 · NCT06609226A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
- NYC Health+Hospitals, Brooklyn
- Interfaith Medical Center, Brooklyn
- Cohen Children's Medical Ctr, Queens
- ja veel 2
VärbamineFaas 3
Vanused 12 ja vanemad · Kõik sood · Uuendatud 17. sept 2026 · NCT06612268A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD
- Icahn School of Medicine at Mount Sinai, New York
- Jacobi Medical Center, The Bronx
VärbamineFaas 2/3
Vanused 12 ja vanemad · Kõik sood · Uuendatud 18. aug 2026 · NCT05431088ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
- Western New York BloodCare, Buffalo
- Northwell Health Hemostasis and Thrombosis Center at Long Island Jewish and Cohen Children's Medical Center, Hyde Park
- Weill Cornell Medical College - New York Presbyterian Hospital, New York
- ja veel 2
VärbamineVaatlusuuring
Kõik vanused · Kõik sood · Uuendatud 17. aug 2026 · NCT04398628Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
- Mount Sinai Medical Center, New York
- Jacobi Medical Center, The Bronx
VärbamineFaas 2
Vanused 12 ja vanemad · Kõik sood · Uuendatud 14. aug 2026 · NCT06699849Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
- Jacobi Medical Center, The Bronx
VärbamineFaas 2
Vanused 18 ja vanemad · Kõik sood · Uuendatud 5. aug 2026 · NCT07224360The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
- Richmond University Medical Center- Site Number : 8400038, Staten Island
- Montefiore Medical Center - Moses Campus- Site Number : 8400057, The Bronx
VärbamineFaas 3
Vanused 10–65 · Kõik sood · Uuendatud 29. juuli 2026 · NCT06975865Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
- New York Medical College, Valhalla
VärbamineFaas 2
6 Months – 21 Years · Kõik sood · Uuendatud 27. juuli 2026 · NCT02675959Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease
- Columbia University Irving Medical Center, New York
- Memorial Sloan Kettering, New York
VärbamineFaas 1/2
Vanused 12–50 · Kõik sood · Uuendatud 2. juuli 2026 · NCT04819841131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD)
- Columbia University Irving Medical Center, New York
VärbamineFaas 1
Vanused 12–50 · Kõik sood · Uuendatud 10. juuni 2026 · NCT07015684Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease
- Roswell Park (MRD-HCT), Buffalo
- Columbia Presbytarian (NT-DMT), New York
- Cohen's Children Hospital (NT-DMT), Queens
- ja veel 4
VärbamineVaatlusuuring
Vanused 3–20 · Kõik sood · Uuendatud 4. juuni 2026 · NCT06941389A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
- Memorial Sloan Kettering Suffolk - Commack (Consent only), Commack
- Memorial Sloan Kettering Westchester (Consent only), Harrison
- Memorial Sloan Kettering Nassau (All protocol activities), Rockville Centre
VärbamineFaas 2
Vanused 2–50 · Kõik sood · Uuendatud 3. juuni 2026 · NCT05736419Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
- New York Presbyterian Hospital - Morgan Stanley Children's Hospital, New York
VärbamineFaas 3
Vanused 12–35 · Kõik sood · Uuendatud 23. märts 2026 · NCT05477563Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease
- Columbia University, New York
VärbamineFaas 2
Vanused 2–25 · Kõik sood · Uuendatud 10. märts 2026 · NCT03587272A Long-term Follow-up Study in Patients Who Received BEAM-101
- Columbia University Irving Medical Center, New York
VärbamineVaatlusuuring
Vanused 14–37 · Kõik sood · Uuendatud 28. jaan 2026 · NCT07373639Peer Support for Adolescents and Emerging Adults With Sickle Cell Pain
- Weil Cornell Medical College, New York
- University of Rochester Medical Center, Rochester
Värbamine
Vanused 16–30 · Kõik sood · Uuendatud 7. jaan 2026 · NCT06374238Cannabinoids for the Reduction of Inflammation and Sickle Cell Related Pain
- Mount Sinai Hospital, New York
VärbamineFaas 2
Vanused 18 ja vanemad · Kõik sood · Uuendatud 2. okt 2025 · NCT05519111AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion
- New York Medical College, Valhalla
VärbamineFaas 2
1 Day – 30 Years · Kõik sood · Uuendatud 8. aug 2025 · NCT04099966Cannabidiol in Sickle Cell Disease
- Icahn School of Medicine at Mount Sinai, Manhattan
VärbamineFaas 1/2
Vanused 18 ja vanemad · Kõik sood · Uuendatud 25. juuni 2025 · NCT06930703Allikas ClinicalTrials.gov, andmed saadud 5. okt 2026. Igal uuringul on oma osalemiskõlblikkuse tingimused; uuringumeeskond otsustab, kes saab osaleda.